

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA - Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No equalities issues were identified by consultees during the scoping process.

No changes were made to the scope regarding equalities issues.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No equality issues have been raised in submissions, expert statements or academic reports.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No equality issues were identified by the Committee during the first or second Committee meetings.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other

groups? If so, what are the barriers to access for the specific group?
No.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
The summary tables in the first and second appraisal consultation documents explain that no equality issues relating to this appraisal have been raised to date.

Approved by Associate Director (name): Elisabeth George

Date: 22/02/2011

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
No equality issues were raised during consultation on either the first or second appraisal consultation documents.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No. The technology is recommended.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The summary table in the FAD states that no equality issues were raised during the scoping process or during the course of the appraisal.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 28 04 11